Future Fertility appoints TMRW Life Sciences executive Louis Villalba to its board of directors

Toronto-based Future Fertility has added tenured industry executive Louis Villalba to their board of directors.

Future Fertility develops AI-based decision support tools to help optimise the fertility journey, with a focus on the oocyte – the human egg.

The company’s non-invasive oocyte assessment software is the first to deliver personalised AI-powered egg quality insights, paving the way for a new standard of care by empowering patients and providers with individualised predictions for blastocyst formation and live birth.

“We have big ambitions globally as we shift into commercial growth mode in 2023,” says Christy Prada, CEO of Future Fertility.

“Lou brings the perfect mix of industry and commercial experience to round out our board team. We are lucky to have the opportunity to learn from him as we further grow our work with fertility clinics and patients globally.”

Louis S. Villalba brings more than 30 years of industry experience in developing and commercialising innovative products and therapies.

Mr Villalba is currently serving as chief business officer at TMRW Life Sciences. Previously he served as chief executive officer of Genea Biomedx, EVP of Corporate Development at OvaScience, EVP of sales at Auxogyn / Progyny and EVP of Europe for Conceptus from 2004 to 2013 where he was part of the team that completed the $1.1B sale of the company to Bayer AG.

“Future Fertility has developed a very interesting and compelling technology, hitting an important niche in the market.  They are the first and only commercially available AI product in the oocyte assessment space and have a clear first-mover advantage,” says Villalba.

“I look forward to working with Christy and the senior management team to focus on developing commercial strategies that make Future Fertility’s AI software a standard of care in reproductive health around the world.”

Villalba’s industry expertise complements Future Fertility’s current board of directors as the company rapidly grows its presence globally, combining Whitecap Ventures’ expertise in scaling technology start-ups, M Ventures’ experience in MedTech commercialisation and co-founder Rene Bharti’s global business experience.

For more info, visit futurefertility.com.